Free sample extract of Forecast: Hemophilia.
By Hardik Patel, Lead Analyst
15 April 2016
I am Lead Analyst for oncology at Datamonitor Healthcare, based in the New York office. I have a Bachelor of Science deg...
Read full bio
Datamonitor Healthcare’s latest patient-based hemophilia forecast delves into branded recombinant therapies, plasma-derived therapies, and pipeline products for the treatment of hemophilia across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK).
Our research, based on epidemiology, primary research, and secondary sources shows that the hemophilia market is set to grow by over $2.4bn during the years 2014 to 2023, representing a compound annual growth rate of 2.4%.
Datamonitor Healthcare analyses the market dynamics, key therapies and the future pipelines, enabling you to successfully position your product in the hemophilia market to ensure your company remains ahead of the competition.
This sample extract highlights:
– Sales of long-acting therapies for hemophilia A and hemophilia B across the US, Japan, and five major EU markets
– Treatment strategies for hemophilia A and B
– Frequency and severity of bleeding events in hemophilia
– Datamonitor Healthcare’s forecast assumptions for Kogenate, Bayer’s hemophilia A treatment
Explore our Hemophilia forecast by downloading your exclusive extract from this market leading report >>
P.S. Keep an eye out for our survey of 210 hematologists and their hemophilia prescribing trends, to be published this summer
Posted in Uncategorized.